Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Steris plc is expanding its surgical products portfolio through a $2.1 billion agreement to acquire Xodus Medical, a Pennsylvania-based manufacturer specializing in surgical safety and operating room consumables.</li><li>Announced on October 12, 2026, the transaction would add Xodus' flagship Pink Pad patient-positioning system and other specialty products to Steris' established healthcare platform.</li><li>The acquisition comes as Steris reported 7% revenue growth and 6% constant-currency organic growth in its first quarter of fiscal 2027, supported by strength in healthcare consumables and services.</li></ul>

Steris plc is expanding its surgical products portfolio through a $2.1 billion agreement to acquire Xodus Medical, a Pennsylvania-based manufacturer specializing in surgical safety and operating room consumables.Announced on October 12, 2026, the transaction would add Xodus' flagship Pink Pad patient-positioning system and other specialty products to Steris' established healthcare platform.The acquisition comes as Steris reported 7% revenue growth and 6% constant-currency organic growth in its first quarter of fiscal 2027, supported by strength in healthcare consumables and services.

Steris' $2.1 Billion Xodus Buyout: Four Major Synergies That Could Reshape Its Growth!

<ul><li>STERIS plc reported its financial and operational results for the first quarter of fiscal 2027, showing modest growth across its key segments amid a complex operating environment.</li><li>The company achieved 7% as-reported revenue growth and 6% constant currency organic revenue growth, driven by both volume increases and pricing actions.</li><li>Gross margin expanded by 70 basis points to 46%, supported by favorable pricing and productivity gains, though partially offset by inflationary pressures.</li></ul>

STERIS plc reported its financial and operational results for the first quarter of fiscal 2027, showing modest growth across its key segments amid a complex operating environment.The company achieved 7% as-reported revenue growth and 6% constant currency organic revenue growth, driven by both volume increases and pricing actions.Gross margin expanded by 70 basis points to 46%, supported by favorable pricing and productivity gains, though partially offset by inflationary pressures.

STERIS plc’s $600 Million Expansion — A $700 Million Chemistry Business Gets Bigger!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>
<a href="https://smartkarma.com/entities/steris-plc">STERIS </a>is a global leader in infection prevention and sterilization, operating a resilient 'razor-and-blade' business model with approximately 75% of revenue being recurring.</li>
  <li>The company demonstrates strong growth, driven by increasing surgical volumes, a heightened focus on preventing healthcare-associated infections, and the trend of outsourcing sterilization services.</li>
  <li>While facing inflationary pressures and supply chain complexities, STERIS's entrenched market position, extensive service network, and high customer switching costs provide a durable competitive advantage.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
STERIS is a global leader in infection prevention and sterilization, operating a resilient 'razor-and-blade' business model with approximately 75% of revenue being recurring.
  The company demonstrates strong growth, driven by increasing surgical volumes, a heightened focus on preventing healthcare-associated infections, and the trend of outsourcing sterilization services.
  While facing inflationary pressures and supply chain complexities, STERIS's entrenched market position, extensive service network, and high customer switching costs provide a durable competitive advantage.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul><li>STERIS plc reported financial results for fiscal year 2026 reflecting a mixed but overall steady performance amid ongoing economic and operational challenges.</li><li>The company posted a 7% increase in reported revenue in the fourth quarter and 9% growth for the full year, with constant currency organic revenue growth at 5% for the quarter and 7% for the year.</li><li>Growth was driven primarily by volume increases and pricing gains, with approximately 230 basis points of price benefit in Q4.</li></ul>

STERIS plc reported financial results for fiscal year 2026 reflecting a mixed but overall steady performance amid ongoing economic and operational challenges.The company posted a 7% increase in reported revenue in the fourth quarter and 9% growth for the full year, with constant currency organic revenue growth at 5% for the quarter and 7% for the year.Growth was driven primarily by volume increases and pricing gains, with approximately 230 basis points of price benefit in Q4.

STERIS’ $400 Million Healthcare Backlog Puts Equipment Demand Back In Focus!

<ul><li>STERIS plc reported its third-quarter results for fiscal year 2026, highlighting both growth and challenges.</li><li>The company's revenue increased by 9% year-over-year, with constant currency organic revenue growth at 8%.</li><li>This growth was fueled by volume increases and a favorable pricing environment that contributed 200 basis points to revenue growth.</li></ul>

STERIS plc reported its third-quarter results for fiscal year 2026, highlighting both growth and challenges.The company's revenue increased by 9% year-over-year, with constant currency organic revenue growth at 8%.This growth was fueled by volume increases and a favorable pricing environment that contributed 200 basis points to revenue growth.

STERIS: Is Its Aggressive EMEA Push the Hidden Catalyst Investors Are Overlooking?

United States

STERIS Public Limited Company operates as a provider of infection prevention and other procedural products and services. The Company offers sterilizers and washers, surgical tables, lights and equipment management systems, and endoscopy accessories. STERIS serves healthcare, pharmaceutical, and medical device industries.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

STERIS (STE US)

Steris' $2.1 Billion Xodus Buyout: Four Major Synergies That Could Reshape Its Growth!

Steris plc is expanding its surgical products portfolio through a $2.1 billion agreement to acquire Xodus Medical, a Pennsylvania-based...

Baptista Research

STERIS plc’s $600 Million Expansion — A $700 Million Chemistry Business Gets Bigger!

STERIS plc reported its financial and operational results for the first quarter of fiscal 2027, showing modest growth across its key segments amid...

Baptista Research

Primer: STERIS (STE US) - Aug 2026

STERIS is a global leader in infection prevention and sterilization, operating a resilient 'razor-and-blade' business model with approximately...

αSK Primers

STERIS’ $400 Million Healthcare Backlog Puts Equipment Demand Back In Focus!

STERIS plc reported financial results for fiscal year 2026 reflecting a mixed but overall steady performance amid ongoing economic and operational...

Baptista Research

STERIS: Is Its Aggressive EMEA Push the Hidden Catalyst Investors Are Overlooking?

STERIS plc reported its third-quarter results for fiscal year 2026, highlighting both growth and challenges. The company's revenue increased by 9%...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)